Stock Pick: Helmerich & Payne Drilling Company (HP)

by Tarik Pierce on October 8, 2006

Helmerich & Payne (HP) is making money hand over fist with their oil drilling and real estate assets. While the major gas distributors like BP and Exxon are facing decreasing margins due to the falling price of gas, the drillers are still making money hand over fist.

3 Reasons Why Helmerich & Payne is A Top Stock Pick

HP is a Best of Breed company

Their long history of profits and forward movement puts them ahead of the competition in terms of dollars earned per rig and per day.

They Produce the Most Efficient Oil Rigs (aka FlexRigs) In the Drilling Industry

A flexRig is a device which is used to pump oil from underground to the surface. Their trademark FlexRigs are both safer and much more efficient than the traditional oil rig. Thus giving them a competitive advantage over their competitors. Hp’s Flexrigs reach efficiency ratios up to 53% better than traditional rigs, and its average daily cost of use is around $6,000 more than the traditional rig. This should mean BIG bucks for HP Investors.

HP’s stock is HIGHLY discounted

Using the Discounted Cash Flow model, HP’s stock is worth around $92 using a DCF average. Aperion analyst Lewis Kreps has a $60 price target as well. Also, HP offers 75% margin of safety which makes it a worthwhile investment.

Helmerich and Payne’s competitive advantage of the oil drilling industry makes this company a good stock pick.

If you enjoyed this article, please subscribe to our free stock market newsletter and receive a 10-day email course on successful stock market strategies

{ 4 trackbacks }

3 Oil & Metal Stock Picks
February 11, 2007 at 2:50 pm
Portfolio Watch: HP, EFJI, BUD
April 16, 2007 at 11:41 am
101 Stocks for the Future - Part 1
April 29, 2007 at 7:51 pm
Managing My Investment Portfolio
May 24, 2007 at 12:21 pm

{ 1 comment… read it below or add one }

mlgreen8753 September 16, 2009 at 9:30 pm

That sounds great, but I think I will stick with bio-tech stocks. Well I can use all the advice I can get. Mentor Capital (MNTR) is not a bio-tech company, but they have a 20% interest in one that is working on FDA approved clinical trials for a new breast cancer treatment that is safer than existing treatments and has only flu-like side effects. Their ties to the company can result in price gains.

Leave a Comment